Actinic Keratosis News and Research

RSS
Actinic keratosis, also known as solar keratosis, is a dry, scaly patch of skin that presents as a result of chronic exposure to sunlight. Most people with the condition do not report significant symptoms, although the condition can progress to a type of skin cancer, squamous cell carcinoma, in severe cases without treatment.
New study shows added benefit of ingenol mebutate for patients with actinic keratosis

New study shows added benefit of ingenol mebutate for patients with actinic keratosis

French scientists develop new wearable laser that eradicates skin conditions

French scientists develop new wearable laser that eradicates skin conditions

Generic skin cream may reduce squamous cell carcinoma risk

Generic skin cream may reduce squamous cell carcinoma risk

Papillomaviruses linked to UV light promote development of non-melanoma skin cancer

Papillomaviruses linked to UV light promote development of non-melanoma skin cancer

Combination therapy holds great promise to clear precancerous skin lesions

Combination therapy holds great promise to clear precancerous skin lesions

Study shows new drug combination effective in treating precancerous skin lesions

Study shows new drug combination effective in treating precancerous skin lesions

Common bacteria on human skin may offer protection against diseases

Common bacteria on human skin may offer protection against diseases

Cipher strengthens Canadian dermatology portfolio with acquisition of Vaniqa, Actikerall

Cipher strengthens Canadian dermatology portfolio with acquisition of Vaniqa, Actikerall

Kinex Pharmaceuticals doses first actinic keratosis patient with KX2-391 ointment

Kinex Pharmaceuticals doses first actinic keratosis patient with KX2-391 ointment

New actinic keratoses data presented at the 15th World Congress of Cancers of the Skin

New actinic keratoses data presented at the 15th World Congress of Cancers of the Skin

Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

BioLineRx announces financial results for Q1 2014, provides operational update

BioLineRx announces financial results for Q1 2014, provides operational update

PhotoMedex revenues decrease 12% to $50.1 million in first quarter 2014

PhotoMedex revenues decrease 12% to $50.1 million in first quarter 2014

PhotoMedex Q4 2013 revenues up 16% to $63.5 million

PhotoMedex Q4 2013 revenues up 16% to $63.5 million

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

PhotoMedex terminates exclusive distribution agreement between Radiancy and Ya-Man in Japan

PhotoMedex terminates exclusive distribution agreement between Radiancy and Ya-Man in Japan

PhotoMedex third quarter 2013 revenues decrease 19% to $45.9 million

PhotoMedex third quarter 2013 revenues decrease 19% to $45.9 million

Physician treatment perceptions in actinic keratosis: an interview with Kim Kjøller, Senior Vice President for Global Development, LEO Pharma

Physician treatment perceptions in actinic keratosis: an interview with Kim Kjøller, Senior Vice President for Global Development, LEO Pharma

New study highlights that physicians prefer topical therapies for actinic keratosis

New study highlights that physicians prefer topical therapies for actinic keratosis

PhotoMedex introduces NEOVA's hyper-active moisturizer, DNA Barrier Accelerator

PhotoMedex introduces NEOVA's hyper-active moisturizer, DNA Barrier Accelerator